1,1-dichloroethene decreases expression ISO RGD:1551507 6480464 vinylidene chloride results in decreased expression of PLOD2 mRNA CTD PMID:26682919 1,2-dimethylhydrazine increases expression ISO RGD:1551507 6480464 1, 2-Dimethylhydrazine results in increased expression of PLOD2 mRNA CTD PMID:22206623 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of PLOD2 mRNA CTD PMID:25380136 , PMID:30723492 17alpha-ethynylestradiol increases expression EXP 6480464 Ethinyl Estradiol results in increased expression of PLOD2 mRNA CTD PMID:12075121 17beta-estradiol increases expression ISO RGD:1606836 6480464 Estradiol results in increased expression of PLOD2 mRNA CTD PMID:20106945 17beta-estradiol multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLOD2 mRNA CTD PMID:32741896 17beta-estradiol increases expression ISO RGD:1551507 6480464 Estradiol results in increased expression of PLOD2 mRNA CTD PMID:19484750 17beta-estradiol multiple interactions ISO RGD:1606836 6480464 [Estradiol binds to ESR2 protein] which results in increased expression of PLOD2 mRNA, [Estradiol co-treated with TGFB1 protein] results in increased expression of PLOD2 mRNA CTD PMID:20404318 , PMID:30165855 17beta-estradiol affects expression ISO RGD:1606836 6480464 Estradiol affects the expression of PLOD2 mRNA CTD PMID:14699072 17beta-estradiol 3-benzoate multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLOD2 mRNA CTD PMID:32741896 17beta-hydroxy-5alpha-androstan-3-one increases expression ISO RGD:1606836 6480464 Dihydrotestosterone results in increased expression of PLOD2 mRNA CTD PMID:29581250 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1551507 6480464 Tetrachlorodibenzodioxin results in decreased expression of PLOD2 mRNA CTD PMID:18691609 , PMID:19770486 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of PLOD2 mRNA CTD PMID:34747641 2,4,6-trinitrobenzenesulfonic acid increases expression ISO RGD:1551507 6480464 Trinitrobenzenesulfonic Acid results in increased expression of PLOD2 mRNA CTD PMID:18200517 2,4,6-trinitrobenzenesulfonic acid multiple interactions ISO RGD:1551507 6480464 Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PLOD2 mRNA] CTD PMID:18200517 2-hydroxypropanoic acid decreases expression ISO RGD:1606836 6480464 Lactic Acid results in decreased expression of PLOD2 mRNA CTD PMID:30851411 4,4'-diaminodiphenylmethane increases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in increased expression of PLOD2 mRNA CTD PMID:25380136 4,4'-diaminodiphenylmethane increases expression ISO RGD:1551507 6480464 4, 4'-diaminodiphenylmethane results in increased expression of PLOD2 mRNA CTD PMID:18648102 4,4'-sulfonyldiphenol increases expression ISO RGD:1551507 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of PLOD2 mRNA CTD PMID:30951980 4-hydroxyphenyl retinamide increases expression ISO RGD:1551507 6480464 Fenretinide results in increased expression of PLOD2 mRNA CTD PMID:28973697 5-fluorouracil increases expression ISO RGD:1606836 6480464 Fluorouracil results in increased expression of PLOD2 protein CTD PMID:15352031 5-fluorouracil decreases expression ISO RGD:1606836 6480464 Fluorouracil results in decreased expression of PLOD2 mRNA CTD PMID:16557594 5-fluorouracil affects response to substance ISO RGD:1606836 6480464 PLOD2 protein affects the susceptibility to Fluorouracil CTD PMID:15352031 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of PLOD2 mRNA CTD PMID:24780913 acrylamide decreases expression ISO RGD:1606836 6480464 Acrylamide results in decreased expression of PLOD2 mRNA CTD PMID:32763439 aflatoxin B1 increases expression ISO RGD:1551507 6480464 Aflatoxin B1 results in increased expression of PLOD2 mRNA CTD PMID:19770486 aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of PLOD2 mRNA CTD PMID:33354967 aflatoxin B1 increases methylation ISO RGD:1606836 6480464 Aflatoxin B1 results in increased methylation of PLOD2 intron CTD PMID:30157460 aflatoxin B1 increases expression ISO RGD:1606836 6480464 Aflatoxin B1 results in increased expression of PLOD2 mRNA CTD PMID:27153756 aflatoxin B1 decreases methylation ISO RGD:1606836 6480464 Aflatoxin B1 results in decreased methylation of PLOD2 gene CTD PMID:27153756 aflatoxin M1 decreases expression ISO RGD:1606836 6480464 Aflatoxin M1 results in decreased expression of PLOD2 mRNA CTD PMID:30928695 aldehydo-D-glucose increases expression ISO RGD:1551507 6480464 Glucose results in increased expression of PLOD2 mRNA CTD PMID:17178593 all-trans-retinoic acid increases expression ISO RGD:1606836 6480464 Tretinoin results in increased expression of PLOD2 mRNA CTD PMID:17138961 , PMID:21934132 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of PLOD2 mRNA CTD PMID:16483693 amphetamine increases expression EXP 6480464 Amphetamine results in increased expression of PLOD2 mRNA CTD PMID:30779732 aristolochic acid A decreases expression ISO RGD:1606836 6480464 aristolochic acid I results in decreased expression of PLOD2 mRNA CTD PMID:33212167 arsane multiple interactions ISO RGD:1606836 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of PLOD2 mRNA CTD PMID:32525701 arsenic atom multiple interactions ISO RGD:1606836 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of PLOD2 mRNA CTD PMID:32525701 benzo[a]pyrene increases expression ISO RGD:1551507 6480464 Benzo(a)pyrene results in increased expression of PLOD2 mRNA CTD PMID:19770486 benzo[a]pyrene increases expression ISO RGD:1606836 6480464 Benzo(a)pyrene results in increased expression of PLOD2 mRNA CTD PMID:32234424 benzo[a]pyrene decreases methylation ISO RGD:1606836 6480464 Benzo(a)pyrene results in decreased methylation of PLOD2 5' UTR, Benzo(a)pyrene results in decreased methylation of PLOD2 promoter CTD PMID:27901495 beta-naphthoflavone multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PLOD2 mRNA CTD PMID:18164116 beta-naphthoflavone decreases expression ISO RGD:1606836 6480464 beta-Naphthoflavone results in decreased expression of PLOD2 mRNA CTD PMID:32858204 bexarotene increases expression ISO RGD:1606836 6480464 bexarotene results in increased expression of PLOD2 mRNA CTD PMID:17178900 bis(2-chloroethyl) sulfide increases expression ISO RGD:1551507 6480464 Mustard Gas results in increased expression of PLOD2 mRNA CTD PMID:15674844 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of PLOD2 mRNA CTD PMID:12075121 , PMID:25181051 bisphenol A multiple interactions ISO RGD:1606836 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of PLOD2 gene CTD PMID:31601247 bisphenol A decreases methylation ISO RGD:1606836 6480464 bisphenol A results in decreased methylation of PLOD2 gene CTD PMID:31601247 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of PLOD2 mRNA CTD PMID:34947998 bisphenol A affects expression ISO RGD:1606836 6480464 bisphenol A affects the expression of PLOD2 mRNA CTD PMID:30903817 bisphenol A decreases expression ISO RGD:1606836 6480464 bisphenol A results in decreased expression of PLOD2 mRNA, bisphenol A results in decreased expression of PLOD2 protein CTD PMID:29275510 , PMID:34186270 bisphenol A increases expression ISO RGD:1551507 6480464 bisphenol A results in increased expression of PLOD2 mRNA CTD PMID:25594700 , PMID:30951980 Bisphenol B increases expression ISO RGD:1606836 6480464 bisphenol B results in increased expression of PLOD2 protein CTD PMID:34186270 bisphenol F increases expression ISO RGD:1551507 6480464 bisphenol F results in increased expression of PLOD2 mRNA CTD PMID:30951980 bisphenol F increases expression ISO RGD:1606836 6480464 bisphenol F results in increased expression of PLOD2 protein CTD PMID:34186270 butan-1-ol multiple interactions ISO RGD:1606836 6480464 [[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PLOD2 mRNA CTD PMID:29432896 cadmium dichloride decreases expression ISO RGD:1551507 6480464 Cadmium Chloride results in decreased expression of PLOD2 mRNA CTD PMID:24982889 cadmium dichloride increases expression EXP 6480464 Cadmium Chloride results in increased expression of PLOD2 mRNA CTD PMID:25993096 cadmium sulfate increases expression ISO RGD:1606836 6480464 cadmium sulfate results in increased expression of PLOD2 mRNA CTD PMID:12064557 , PMID:14676411 carbon nanotube decreases expression ISO RGD:1551507 6480464 Nanotubes more ... CTD PMID:25554681 CGP 52608 multiple interactions ISO RGD:1606836 6480464 CGP 52608 promotes the reaction [RORA protein binds to PLOD2 gene] CTD PMID:28238834 chloropicrin affects expression ISO RGD:1606836 6480464 chloropicrin affects the expression of PLOD2 mRNA CTD PMID:26352163 chloropicrin decreases expression ISO RGD:1606836 6480464 chloropicrin results in decreased expression of PLOD2 mRNA CTD PMID:28476498 choline multiple interactions ISO RGD:1551507 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of PLOD2 more ... CTD PMID:20938992 ciglitazone decreases expression EXP 6480464 ciglitazone results in decreased expression of PLOD2 mRNA CTD PMID:22193206 cisplatin multiple interactions ISO RGD:1606836 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of PLOD2 mRNA CTD PMID:27392435 cisplatin decreases expression ISO RGD:1606836 6480464 Cisplatin results in decreased expression of PLOD2 mRNA CTD PMID:27392435 cobalt atom multiple interactions ISO RGD:1606836 6480464 [tungsten carbide binds to Cobalt] which results in increased expression of PLOD2 mRNA CTD PMID:20105288 cobalt dichloride increases expression ISO RGD:1606836 6480464 cobaltous chloride results in increased expression of PLOD2 mRNA CTD PMID:19376846 , PMID:20105288 copper atom multiple interactions ISO RGD:1606836 6480464 [Disulfiram binds to Copper] which results in increased expression of PLOD2 mRNA, [NSC 689534 binds to Copper] which results in increased expression of PLOD2 mRNA CTD PMID:20971185 , PMID:24690739 copper(0) multiple interactions ISO RGD:1606836 6480464 [Disulfiram binds to Copper] which results in increased expression of PLOD2 mRNA, [NSC 689534 binds to Copper] which results in increased expression of PLOD2 mRNA CTD PMID:20971185 , PMID:24690739 copper(II) sulfate increases expression ISO RGD:1606836 6480464 Copper Sulfate results in increased expression of PLOD2 mRNA CTD PMID:19549813 coumestrol multiple interactions ISO RGD:1606836 6480464 [Coumestrol co-treated with 2 more ... CTD PMID:19167446 curcumin multiple interactions ISO RGD:1551507 6480464 Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PLOD2 mRNA] CTD PMID:18200517 cyclosporin A affects expression ISO RGD:1606836 6480464 Cyclosporine affects the expression of PLOD2 mRNA CTD PMID:20106945 cyclosporin A decreases expression ISO RGD:1606836 6480464 Cyclosporine results in decreased expression of PLOD2 mRNA CTD PMID:21632981 more ... cyclosporin A decreases expression ISO RGD:1551507 6480464 Cyclosporine results in decreased expression of PLOD2 mRNA CTD PMID:19770486 D-glucose increases expression ISO RGD:1551507 6480464 Glucose results in increased expression of PLOD2 mRNA CTD PMID:17178593 dexamethasone decreases expression ISO RGD:1606836 6480464 Dexamethasone results in decreased expression of PLOD2 mRNA CTD PMID:25047013 dextran sulfate multiple interactions ISO RGD:1551507 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLOD2 mRNA CTD PMID:29950665 dicrotophos decreases expression ISO RGD:1606836 6480464 dicrotophos results in decreased expression of PLOD2 mRNA CTD PMID:28302478 dimethyl sulfoxide increases expression EXP 6480464 Dimethyl Sulfoxide results in increased expression of PLOD2 mRNA CTD PMID:22193206 dioxygen multiple interactions ISO RGD:1606836 6480464 HIF1A mutant form inhibits the reaction [Oxygen deficiency results in increased expression of PLOD2 mRNA] CTD PMID:23423382 dioxygen increases expression ISO RGD:1606836 6480464 Oxygen deficiency results in increased expression of PLOD2 mRNA CTD PMID:20042640 more ... disulfiram multiple interactions ISO RGD:1606836 6480464 [Disulfiram binds to Copper] which results in increased expression of PLOD2 mRNA CTD PMID:24690739 dorsomorphin multiple interactions ISO RGD:1606836 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxifluridine decreases response to substance ISO RGD:1606836 6480464 PLOD2 protein results in decreased susceptibility to doxifluridine CTD PMID:16734730 doxorubicin decreases expression ISO RGD:1606836 6480464 Doxorubicin results in decreased expression of PLOD2 mRNA CTD PMID:29803840 elemental selenium decreases expression ISO RGD:1606836 6480464 Selenium results in decreased expression of PLOD2 mRNA CTD PMID:19244175 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of PLOD2 mRNA CTD PMID:29391264 Enterolactone multiple interactions ISO RGD:1606836 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PLOD2 mRNA CTD PMID:19167446 entinostat increases expression ISO RGD:1606836 6480464 entinostat results in increased expression of PLOD2 mRNA CTD PMID:26272509 entinostat multiple interactions ISO RGD:1606836 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA CTD PMID:27188386 enzalutamide decreases expression ISO RGD:1606836 6480464 enzalutamide results in decreased expression of PLOD2 mRNA CTD PMID:29581250 ethanol increases expression ISO RGD:1606836 6480464 Ethanol results in increased expression of PLOD2 mRNA CTD PMID:15997088 , PMID:23378141 ethanol multiple interactions ISO RGD:1606836 6480464 [[Gasoline co-treated with Ethanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PLOD2 mRNA, [Ethanol co-treated with Folic Acid] results in increased expression of PLOD2 mRNA CTD PMID:23378141 , PMID:29432896 ethanol multiple interactions ISO RGD:1551507 6480464 [Carbon Tetrachloride co-treated with Ethanol] results in increased expression of PLOD2 mRNA CTD PMID:30517762 ethyl methanesulfonate decreases expression ISO RGD:1606836 6480464 Ethyl Methanesulfonate results in decreased expression of PLOD2 mRNA CTD PMID:23649840 folic acid multiple interactions ISO RGD:1551507 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of PLOD2 more ... CTD PMID:20938992 folic acid multiple interactions ISO RGD:1606836 6480464 [Ethanol co-treated with Folic Acid] results in increased expression of PLOD2 mRNA CTD PMID:23378141 fonofos increases methylation ISO RGD:1606836 6480464 Fonofos results in increased methylation of PLOD2 promoter CTD PMID:22847954 fulvestrant multiple interactions ISO RGD:1606836 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of PLOD2 gene CTD PMID:31601247 furan increases expression EXP 6480464 furan results in increased expression of PLOD2 mRNA CTD PMID:27387713 furan decreases methylation EXP 6480464 furan results in decreased methylation of PLOD2 gene CTD PMID:27387713 genistein increases expression EXP 6480464 Genistein results in increased expression of PLOD2 mRNA CTD PMID:12075121 glucose increases expression ISO RGD:1551507 6480464 Glucose results in increased expression of PLOD2 mRNA CTD PMID:17178593 isoniazide increases expression ISO RGD:1606836 6480464 Isoniazid results in increased expression of PLOD2 mRNA CTD PMID:15997088 ivermectin decreases expression ISO RGD:1606836 6480464 Ivermectin results in decreased expression of PLOD2 protein CTD PMID:32959892 L-methionine multiple interactions ISO RGD:1551507 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of PLOD2 more ... CTD PMID:20938992 lead diacetate decreases expression EXP 6480464 lead acetate results in decreased expression of PLOD2 mRNA CTD PMID:22641619 medroxyprogesterone acetate decreases expression ISO RGD:1606836 6480464 Medroxyprogesterone Acetate results in decreased expression of PLOD2 mRNA CTD PMID:20843944 mercury dibromide increases expression ISO RGD:1606836 6480464 mercuric bromide results in increased expression of PLOD2 mRNA CTD PMID:26272509 mercury dibromide multiple interactions ISO RGD:1606836 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA CTD PMID:27188386 methyl methanesulfonate decreases expression ISO RGD:1606836 6480464 Methyl Methanesulfonate results in decreased expression of PLOD2 mRNA CTD PMID:23649840 methylmercury chloride increases expression ISO RGD:1606836 6480464 methylmercuric chloride results in increased expression of PLOD2 mRNA CTD PMID:23179753 , PMID:26272509 methylmercury chloride multiple interactions ISO RGD:1606836 6480464 [NOG protein co-treated with methylmercuric chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA CTD PMID:27188386 methylmercury chloride decreases expression ISO RGD:1606836 6480464 methylmercuric chloride results in decreased expression of PLOD2 mRNA CTD PMID:27188386 mifepristone increases expression ISO RGD:1606836 6480464 Mifepristone results in increased expression of PLOD2 mRNA CTD PMID:17584828 N-nitrosodiethylamine multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PLOD2 mRNA CTD PMID:18164116 N-nitrosodimethylamine increases expression EXP 6480464 Dimethylnitrosamine results in increased expression of PLOD2 mRNA CTD PMID:25380136 nickel atom increases expression ISO RGD:1606836 6480464 Nickel results in increased expression of PLOD2 mRNA CTD PMID:24768652 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of PLOD2 mRNA CTD PMID:25729387 oxaliplatin increases expression EXP 6480464 oxaliplatin results in increased expression of PLOD2 mRNA CTD PMID:25729387 ozone increases expression EXP 6480464 Ozone results in increased expression of PLOD2 mRNA CTD PMID:16716893 ozone multiple interactions ISO RGD:1551507 6480464 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of PLOD2 mRNA CTD PMID:34911549 panobinostat multiple interactions ISO RGD:1606836 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA CTD PMID:27188386 panobinostat increases expression ISO RGD:1606836 6480464 panobinostat results in increased expression of PLOD2 mRNA CTD PMID:26272509 paracetamol affects expression ISO RGD:1551507 6480464 Acetaminophen affects the expression of PLOD2 mRNA CTD PMID:17562736 paracetamol increases expression ISO RGD:1551507 6480464 Acetaminophen results in increased expression of PLOD2 mRNA CTD PMID:15997088 paracetamol increases expression ISO RGD:1606836 6480464 Acetaminophen results in increased expression of PLOD2 mRNA CTD PMID:15997088 paraquat affects splicing ISO RGD:1551507 6480464 Paraquat affects the splicing of PLOD2 exon CTD PMID:27111068 paraquat increases expression EXP 6480464 Paraquat results in increased expression of PLOD2 mRNA CTD PMID:32680482 parathion increases methylation ISO RGD:1606836 6480464 Parathion results in increased methylation of PLOD2 promoter CTD PMID:22847954 pentane-2,3-dione increases expression EXP 6480464 2, 3-pentanedione results in increased expression of PLOD2 mRNA CTD PMID:25710175 perfluorooctane-1-sulfonic acid decreases expression ISO RGD:1551507 6480464 perfluorooctane sulfonic acid results in decreased expression of PLOD2 protein CTD PMID:26178269 perfluorooctanoic acid increases expression EXP 6480464 perfluorooctanoic acid results in increased expression of PLOD2 mRNA CTD PMID:19162173 phenylmercury acetate increases expression ISO RGD:1606836 6480464 Phenylmercuric Acetate results in increased expression of PLOD2 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1606836 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA CTD PMID:27188386 phosgene affects expression ISO RGD:1551507 6480464 Phosgene affects the expression of PLOD2 mRNA CTD PMID:16300373 progesterone increases expression EXP 6480464 Progesterone results in increased expression of PLOD2 mRNA CTD PMID:21770760 protein kinase inhibitor multiple interactions ISO RGD:1606836 6480464 Protein Kinase Inhibitors inhibits the reaction [gardiquimod results in increased expression of PLOD2 mRNA] CTD PMID:28003376 quercetin decreases expression ISO RGD:1606836 6480464 Quercetin results in decreased expression of PLOD2 mRNA CTD PMID:21632981 rac-lactic acid decreases expression ISO RGD:1606836 6480464 Lactic Acid results in decreased expression of PLOD2 mRNA CTD PMID:30851411 resveratrol multiple interactions ISO RGD:1606836 6480464 [Coumestrol co-treated with resveratrol] results in increased expression of PLOD2 mRNA CTD PMID:19167446 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of PLOD2 mRNA CTD PMID:28374803 Salinomycin decreases expression ISO RGD:1606836 6480464 salinomycin results in decreased expression of PLOD2 mRNA CTD PMID:19682730 SB 431542 multiple interactions ISO RGD:1606836 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 selenium atom decreases expression ISO RGD:1606836 6480464 Selenium results in decreased expression of PLOD2 mRNA CTD PMID:19244175 sodium arsenate decreases expression ISO RGD:1551507 6480464 sodium arsenate results in decreased expression of PLOD2 mRNA CTD PMID:21795629 sodium arsenate multiple interactions ISO RGD:1606836 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of PLOD2 mRNA CTD PMID:32525701 sodium arsenate increases expression ISO RGD:1551507 6480464 sodium arsenate results in increased expression of PLOD2 mRNA CTD PMID:21795629 sunitinib increases expression ISO RGD:1606836 6480464 Sunitinib results in increased expression of PLOD2 mRNA CTD PMID:31533062 tamoxifen increases expression ISO RGD:1551507 6480464 Tamoxifen results in increased expression of PLOD2 mRNA CTD PMID:25123088 Tanshinone I decreases expression ISO RGD:1606836 6480464 tanshinone results in decreased expression of PLOD2 mRNA CTD PMID:15849732 temozolomide increases expression ISO RGD:1606836 6480464 Temozolomide results in increased expression of PLOD2 mRNA CTD PMID:31758290 terbufos increases methylation ISO RGD:1606836 6480464 terbufos results in increased methylation of PLOD2 promoter CTD PMID:22847954 testosterone multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLOD2 mRNA CTD PMID:32741896 testosterone enanthate affects expression ISO RGD:1606836 6480464 testosterone enanthate affects the expression of PLOD2 mRNA CTD PMID:17440010 tetrachloromethane affects expression ISO RGD:1551507 6480464 Carbon Tetrachloride affects the expression of PLOD2 mRNA CTD PMID:17484886 tetrachloromethane multiple interactions ISO RGD:1551507 6480464 [Carbon Tetrachloride co-treated with Ethanol] results in increased expression of PLOD2 mRNA CTD PMID:30517762 tetrachloromethane increases expression EXP 6480464 Carbon Tetrachloride results in increased expression of PLOD2 mRNA CTD PMID:31150632 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of PLOD2 mRNA CTD PMID:34492290 titanium dioxide multiple interactions ISO RGD:1551507 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLOD2 mRNA CTD PMID:29950665 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of PLOD2 mRNA CTD PMID:25729387 topotecan increases expression EXP 6480464 Topotecan results in increased expression of PLOD2 mRNA CTD PMID:25729387 topotecan affects response to substance ISO RGD:1606836 6480464 PLOD2 protein affects the susceptibility to Topotecan CTD PMID:16217747 trichostatin A increases expression ISO RGD:1606836 6480464 trichostatin A results in increased expression of PLOD2 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1606836 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA CTD PMID:27188386 triclosan decreases expression ISO RGD:1606836 6480464 Triclosan results in decreased expression of PLOD2 mRNA CTD PMID:30510588 tris(2-butoxyethyl) phosphate affects expression ISO RGD:1606836 6480464 tris(2-butoxyethyl) phosphate affects the expression of PLOD2 mRNA CTD PMID:29024780 Tungsten carbide multiple interactions ISO RGD:1606836 6480464 [tungsten carbide binds to Cobalt] which results in increased expression of PLOD2 mRNA CTD PMID:20105288 valproic acid affects expression ISO RGD:1606836 6480464 Valproic Acid affects the expression of PLOD2 mRNA CTD PMID:25979313 valproic acid increases expression ISO RGD:1606836 6480464 Valproic Acid results in increased expression of PLOD2 mRNA CTD PMID:23179753 more ... valproic acid multiple interactions ISO RGD:1606836 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA CTD PMID:27188386 vandetanib increases expression ISO RGD:1606836 6480464 vandetanib results in increased expression of PLOD2 mRNA CTD PMID:16052530 vitamin E decreases expression ISO RGD:1606836 6480464 Vitamin E results in decreased expression of PLOD2 mRNA CTD PMID:19244175 vorinostat multiple interactions ISO RGD:1606836 6480464 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA CTD PMID:27188386 vorinostat increases expression ISO RGD:1606836 6480464 vorinostat results in increased expression of PLOD2 mRNA CTD PMID:26272509 Yessotoxin increases expression ISO RGD:1606836 6480464 yessotoxin analog results in increased expression of PLOD2 mRNA CTD PMID:30679557 zoledronic acid increases expression ISO RGD:1606836 6480464 zoledronic acid results in increased expression of PLOD2 mRNA CTD PMID:24714768
